✉news HealthMedicine first seen 4 d ago, last 4 d ago, peak #31

Disc Medicine Shares Surge 30% Ahead of Phase 3 Trial

Original: Disc Medicine (IRON) Shares Surge 30% Ahead of Phase 3 APOLLO Tr

Shares of clinical-stage biotech Disc Medicine jumped roughly 30% ahead of its Phase 3 APOLLO trial. The APOLLO study tests the company's lead drug candidate, bitopertin, in patients with beta-thalassemia. Investors appear to be positioning ahead of data or a key milestone in the trial, driving a sharp spike in the stock's price and trading activity.

Why now: The sharp share price move ahead of a pivotal Phase 3 trial milestone is drawing investor attention.

Disc MedicinebitopertinAPOLLO trial

Open on news →

Evidence

• Disc Medicine (IRON) Shares Surge 30% Ahead of Phase 3 APOLLO Tr · GuruFocus

API: https://socialmediatrends-api.osmike.com/v1/trends/2852714